Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-302168S in Overweight/Obese Subjects
NCT06541730Phase 1Completed
- Sponsor
- Chengdu Diao Pharmaceutical Group
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing DA-302168S with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 49 days. Started Aug 2024; status: completed.
02
Drugs
DA-302168S
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06541730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541730.